Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response

By LabMedica International staff writers
Posted on 10 Feb 2025

Tumor heterogeneity presents a major obstacle in the development and treatment of cancer therapies, as patients' responses to the same drug can differ, and the timing of treatment significantly influences prognosis. Consequently, technologies that predict the effectiveness of anticancer treatments are essential in minimizing side effects and improving treatment efficiency. Current methods, such as gene panel-based tests and patient-derived xenograft (PDX) models, have limitations in their applicability to certain patients, have challenges in predicting drug effects, and require significant time and costs to develop. Now, researchers have successfully created a gastric cancer model using 3D bioprinting technology and patient-derived cancer tissue fragments. This groundbreaking model preserves the characteristics of actual patient tissues and is expected to rapidly assess and predict individual patient drug responses.

In collaborative research by Pohang University of Science & Technology (POSTECH, Gyeongbuk, Korea) and The Jackson Laboratory for Genomic Medicine (Farmington, CT, USA), scientists have developed an in vitro gastric cancer model by utilizing 3D bioprinting technology and tissue-specific bioink that incorporated patient-derived tissue fragments. Notably, they encapsulated cancer tissues within a stomach-derived decellularized extracellular matrix (dECM) hydrogel, which artificially facilitated cell-matrix interactions. By co-culturing these tissues with human gastric fibroblasts, they successfully replicated cancer cell-stroma interactions, thereby recreating the in vivo tumor microenvironment in vitro.

Published in the international journal Advanced Science, the research shows that this model preserved the distinct characteristics of gastric tissues from individual patients by replicating both cell-stroma and cell-matrix interactions. It demonstrated high specificity in predicting the patient's anticancer drug responses and prognosis. Additionally, the model's gene profiles related to cancer development, progression, and drug response closely mirrored those of patient tissues, outperforming conventional PDX models. The rapid fabrication process of this model through bioprinting also allows drug evaluation within two weeks of tumor tissue extraction from the patient. This efficient platform is expected to make a significant contribution to the development of personalized cancer treatments.

“By reproducing cancer cell-stroma and cell-matrix interactions, this model enhances the accuracy of drug response predictions and reduces unnecessary drug administration to non-responsive patients,” said Professor Charles Lee from The Jackson Laboratory for Genomic Medicine, who led the study.

“This is a critical preclinical platform not only for developing patient-specific treatments but also for validating new anticancer drugs and combination therapies,” added Professor Jinah Jang of POSTECH.

Related Links:
POSTECH 
The Jackson Laboratory for Genomic Medicine

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
PSA Test
Humasis PSA Card
New
Fixed Speed Tube Rocker
GTR-FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.